| |
Wednesday, February 26, 2025 | 12pm ET / 9am PT In today’s world, life sciences and healthcare companies face major challenges — managing complex datasets, accelerating drug discovery, and advancing precision research. Register for our webinar to learn how to overcome overcome these challenges using AI cloud infrastructure and advanced machine learning tools. 
|
|
Today’s Big NewsFeb 10, 2025 |
| By James Waldron Boehringer Ingelheim has cemented the potential of its idiopathic pulmonary fibrosis (IPF) drug with a second phase 3 win in a related lung disease leading the drugmaker to expand the indications it will seek FDA approval for. |
|
|
|
By Gabrielle Masson A new initiative rolled out under President Donald Trump’s administration is cutting billions from grants for "indirect costs" tied to biomedical research, such as facilities, equipment and administrative expenses. |
By Nick Paul Taylor Eli Lilly has begun the week with a bang. Early Monday morning, AdvanCell and OliX Pharmaceuticals put out news that the Big Pharma is coughing up cash to work with them on radiopharmaceuticals and metabolic-associated steatohepatitis, respectively. |
By James Waldron Pliant Therapeutics has hit the breaks on a midstage trial of its lead liver disease drug on the advice of its safety committee. |
|
Join us for an expert discussion on how to navigate complex DSCSA requirements in this rapidly advancing field. Explore the systems, processes and technologies that are crucial to safeguard patients. 
|
|
By Nick Paul Taylor Kineta has found a new home for deals with Genentech and Merck & Co. Tidying up the portfolio ahead of its merger with TuHURA Biosciences, the biotech has agreed to sell the deals to an investment firm, offload a pain prospect to Pacira Pharmaceuticals and scrap its pact with GigaGen. |
By Gabrielle Masson After sharing plans to shutter last summer, Asarina Pharma has managed to sell off its Tourette syndrome candidate to Relmada Therapeutics, another struggling biotech. |
By Darren Incorvaia Researchers have used artificial intelligence to identify 25 new protein compounds that can kill bacteria and fungi, including two that showed particular potency against skin and lung infections in mice. |
By Angus Liu With another trial win, Bristol Myers Squibb is touting Breyanzi as the CD19-directed CAR-T therapy with positive readouts in the most cancer types. |
By Conor Hale The procedure was performed January 25 by surgeons at the Mass General Transplant Center in Boston, as part of the company’s clinical study in patients with end-stage renal disease and kidney failure. The MGH previously completed the company’s first xenotransplant surgery in March 2024. |
By Kevin Dunleavy Ten months after Pfizer scored approval in Europe for Emblaveo to treat complicated intra-abdominal infections, AbbVie has done the same in the U.S., winning an FDA nod for Emblaveo for the same type of Gram-negative infections. |
Fierce podcasts Don’t miss an episode |
| This week on "The Top Line," we dig into the 10 biggest potential drug launches of 2025, predicted to rake in a combined $29 billion in annual sales by the end of the decade. |
|
|---|
|
|
Whitepaper This paper reviews key developments in the oncology market during 2024 and outlines what they mean for the future. Presented by Blue Matter, strategic consultants in the life sciences |
| Submissions Open Early August |
|
|
| |
|
